Aldosterone increases plasma volume and may be involved with resistant hypertension. P-glycoprotein is a transporter involved in the distribution and disposition of aldosterone, and is encoded by the MDR-1 gene. MDR-1 has functional polymorphisms that may affect P-glycoprotein expression. We hypothesized that the C 3435 T polymorphism in MDR-1 could be associated with resistant hypertension and with changes in hypertension-related parameters. We studied 105 healthy volunteers, 137 hypertensive patients responsive to treatment, and 83 resistant hypertensive patients. While we found no association of C 3435 T genotypes with resistance to treatment (p = 0.31), C allele was associated with hypertension (p = 0.03). Furthermore, the CC genotype was associated with higher systolic blood pressure (p < 0.01 for both daytime and nighttime, respectively) and diastolic blood pressure (p < 0.01 for both daytime and nighttime, respectively). This effect was probably independent of aldosterone, as we found no differences in aldosterone plasma levels, nor in pulse wave velocity (PVW) between the genotypes groups (p = 0.77 and p = 0.48, respectively). Our results show an association of C 3435 T with hypertension and with blood pressure levels in resistant hypertensive subjects.
Introduction
Hypertension is associated with increased cardiovascular risk and subclinical end-organ damage. 1 Resistant hypertension is defined as a failure to reach target blood pressure despite the use of three anti-hypertensive drug classes at optimal doses (one being a diuretic); or controlled office blood pressure with use of four drugs or more. Careful assessment of resistant hypertension is crucial, as several factors including secondary forms of hypertension (hyperaldosteronism and other conditions), dose titration, patient's compliance with treatment, 2 choice of antihypertensive drug classes, smoking, alcohol and drug abuse are factors that may often add confusion and lead to failure in pharmacological treatment if not addressed correctly. 3, 4 Moreover, chronic kidney disease and other diseases may require dosage and drug class adjustments as patients usually do not achieve target blood pressure levels. 3, 4 Resistant hypertension challenges medical practice, and an improved understanding of its mechanisms and genetic basis may lead to improved therapy. 5, 6 Aldosterone plays important roles in volume-dependent hypertension and may be related to resistance against antihypertensive therapy. 7, 8 Aldosterone worsens the detrimental effects of angiotensin II in cardiovascular remodeling as it modifies the expression of receptors and other cellular components. 9 Indeed, mineralocorticoid receptor antagonists reduce the increased cardiovascular mortality in hypertensive patients 10, 11 and decrease blood pressure 12 in patients with resistant hypertension.
MDR-1 C 3435 T polymorphism may affect blood pressure in resistant hypertensive patients independently of its effects on aldosterone release
P-glycoprotein is an important transporter of drugs and endogenous compounds. However, its role in transporting aldosterone through epithelial barriers has been poorly explored. 13, 14 This transporter is highly expressed in several barriers crossed by aldosterone during its release from adrenals, tissue distribution and renal excretion. [15] [16] [17] [18] Importantly, P-glycoprotein expression modulates aldosterone organ uptake 14 and clearance, 19 possibly explaining why reduced P-glycoprotein expression was associated with dilated cardiomyopathy, an advanced stage of cardiac remodeling. 17 The MDR-1 gene encodes P-glycoprotein, and functional genetic polymorphisms were shown to alter P-glycoprotein expression or substrate specificity. [20] [21] [22] [23] Indeed, these polymorphisms modified the bioavailability of drugs transported by P-glycoprotein 20, 24 and predisposed hypertensive patients to cardiovascular complications. 17, [25] [26] [27] The aim of this study was to assess if MDR-1 C 3435 T genotypes and alleles are associated with resistance to antihypertensive treatment. In addition, we assessed whether genotypes are associated with changes in arterial blood pressure, aldosterone, cortisol and renin plasma levels, or with vascular stiffness in resistant hypertensive patients.
Materials and methods

Subjects
We studied 105 healthy subjects (control group), 137 hypertensive subjects at target blood pressure (CHTN group), and 83 resistant hypertensive subjects (RHTN group), who were classified according to the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines. 4 Resistant hypertensive patients were recruited at the Outpatient Resistant Hypertension Clinic of the State University of Campinas. All patients in the RHTN group had systolic (SBP) and diastolic (DBP) blood pressure above 140 mmHg and 90 mmHg, respectively, concurrent with the use of three different classes of anti-hypertensive drugs (one being a diuretic) or controlled office blood pressure with the use of four drugs or more. 5 Important features such as optimal dosage titration, drug choice (for example, calcium channel blockers were avoided in patients with African ancestry and careful examination of drug-drug interactions was performed) and patient compliance 2 were carefully assessed to ensure resistant hypertension phenotype as described in the current American Heart Association guidelines 5 and in the JNC 7. 4 In addition, non-pharmacological therapies were optimized, including guidance on the control of dietary salt, which was confirmed by the measurement of urinary sodium (< 100 mEq per 24 hours (h)). Controlled hypertensive patients were also recruited at the State University of Campinas and had SBP and DBP below 140 mmHg and 90 mmHg, respectively, with usage of up to three classes of anti-hypertensive drugs. Resistant hypertensive patients as well as patients achieving target blood pressure were excluded if they had secondary forms of hypertension, for example hyperaldosteronism (assessed by plasma aldosterone/renin ratio) and renovascular hypertension (assessed by Doppler ultrasound). We also excluded patients with ischemic heart disease, liver diseases, history of stroke, peripheral vascular diseases, current smokers, chronic kidney disease (ascertained by creatinine clearance below 60 ml/kg/min/m 2 ) or with any other major disease. Finally, the control group included subjects genetically unrelated to the hypertensive patients, with blood pressure below 140 mmHg and 90 mmHg (SBP and DBP, respectively) with no evidence of any disease. All participants signed informed consent, and patients had a previous follow-up for at least six months prior to this study and were compliant to the treatment. Nonpharmacological therapies such as control of dietary salt were optimized and confirmed by measurement of urinary sodium (< 100 mEq/l/24h). This work was approved by the Human Research Ethics Committee at the State University of Campinas.
All hypertensive patients underwent a rigorous clinical examination including electrocardiography and laboratory tests. Briefly, office blood pressure was determined after 15 minutes of rest in a sitting position in a quiet room, using a calibrated sphygmomanometer with a mercury column. All subjects with SBP > 140 mmHg and/or DBP > 90 mmHg on at least three different sets of measurements taken at twoweek intervals were considered hypertensive. 28 Hypertensive patients underwent 24-h ambulatory blood pressure monitoring with an automatic oscillometric device (Spacelabs 90207, Spacelabs Inc, Redmon, WA, USA) in order to confirm the diagnosis. Abstinence from alcohol and nicotine was required for at least 60 minutes prior to blood pressure examination and 12 h prior to pulse wave velocity (PWV) measurements. Venous blood samples were collected after 12 h of fasting, between 08:00 a.m. and 09:00 a.m. for laboratory examinations and DNA extraction. Creatinine clearance (ml/min/1.73 m 2 ) and urinary sodium (mEQ/l) were determined using urine samples collected during 24 h. Compliance to treatment was determined using the tablets count method 29 and Morisky's test. 30 Only patients with administered/prescribed tablets ratio ≥ 0.8 and Morisky's score ≥ 4 were considered adherent. 2, 31 Following clinical examination, all resistant hypertensive patients were submitted to PWV measurements using Complior SP (Artech Medical, Pantin, France) equipment. PWV technique was performed following the manufacturers' instructions. Blood samples drawn from this subset of patients were also used to measure aldosterone, cortisol and renin levels.
Genotyping for the C 3435 T polymorphism in MDR-1 gene
Genomic DNA was extracted from blood samples using a salting-out method. Genotyping for the C 3435 T polymorphism in the MDR-1 gene was performed using allele-specific polymerase chain reaction (PCR). The following primers were used: forward (5΄-TGT TTT CAG CTG CTT GAT GG -3΄), reverse 1, specific for the C allele (5΄-CTT TGC TGC CCT CAC G -3΄), reverse 2, specific for the T allele (5΄-CTT TGC TGC CCT CAC A -3΄), and reverse 3, which acted as an internal control annealing at 20 nucleotides upstream to the polymorphic site (5΄-AAG GCA TGT ATG TTG GCC TC -3΄). PCR was performed under the following conditions: 1× buffer, 0.2 mM dNTPs, 2 mM MgCl 2 , 0.3 µM forward primer, 0.25 µM reverse primer 1 or 2, 0.06 µM reverse primer 3, 1 unit of Taq polymerase (Invitrogen, NY, USA), and 300 ng genomic DNA. The cycles included an initial denaturing step at 94°C for 5 minutes followed by 10 cycles of a denaturing step at 94°C for 30 seconds, annealing step at 61°C for 30 seconds, and extension step at 72°C for 20 seconds, and by 25 cycles of a denaturing step at 94°C for 30 seconds, annealing step at 55°C for 30 seconds and extension step at 72°C for 20 seconds. PCR products were separated by electrophoresis on 12% polyacrylamide gels (PAGE) at 20 mA for four hours at room temperature, and stained with AgNO 3 . The PCR products were visualized as a 197 bp product (as an internal control to assess reaction quality) and a 177 bp product, which was allele specific.
Statistical analysis
Alleles and genotypes distributions were compared using contingency tables (95% confidence intervals (CIs) were obtained by the Clopper and Pearson method). Differences in means between two groups were compared using Student's t test, and analysis of variance (ANOVA) followed by Tukey's post-test when comparing three groups (Stat-View for Windows; SAS Institute, Cary, NC, USA). We considered statistically significant a two-sided p < 0.05. To investigate the effects of the C 3435 T polymorphism on cardiovascular parameters, we focused on the 83 patients with resistant hypertension, and comparisons between different genotype groups were carried out. We confirmed the association of genotypes with arterial blood pressure (assessed by 24-h ambulatory blood pressure monitoring) by a linear regression model. Linear regression analysis and non-linear fitting routines were performed to assess univariate relations between variables (software JMP 5.0.1a; SAS Institute). In addition, a bivariate analysis was also used to assess for the potential confounding influence of each covariate on the relation between MDR-1 genotypes and blood pressure. The variables of clinical importance, as identified by the bivariate approach, were then included in the final multiple linear regression models. We included daytime and nighttime SBP and DBP as dependent variables, and gender, race, age and body mass index (BMI) as independent variables.
Results
All clinical characteristics of the included patients are presented in Table 1 . Although there were some differences in race distribution and BMI, the three groups were similar with respect to gender and age (Table 1) . Moreover, there were no significant differences between the CHTN and the RHTN groups with respect to biochemical parameters ( Table 1) , but creatinine clearance and urinary sodium were reduced in RHTN compared to CHTN (both p < 0.01, Table 1 ).
Genotypes and alleles distributions are shown in Table 2 . The genotype distributions were in Hardy-Weinberg equilibrium in the three groups. We have found a reduced frequency of TT in both CHTN (p = 0.04, Table 2 ) and RHTN (p = 0.02, Table 2 ) when compared to the control group and a reduced frequency of CT genotype in RHTN (p < 0.01, Table 2 ). The allele distributions showed an association between the C allele and both CHTN and RHTN (p = 0.03 and p < 0.01, respectively). In addition, the T allele was associated with protection against hypertension responsive to therapy (odds ratio (OR) = 0.67, 95% CI = 0.47 to 0.96) and against resistant hypertension (OR = 0.57, 95% CI = 0.37 to 0.86). We found no differences in genotypes and alleles frequencies between the CHTN and the RHTN groups.
After evaluating the association of the MDR-1 C3435T polymorphism with hypertension (either responsive or resistant to therapy), we decided to assess whether this polymorphism could affect clinically important parameters in patients with resistant hypertension. Figure 1 shows the effects of the MDR-1 C 3435 T polymorphism on the SBP and DBP, both during daytime and nighttime in resistant hypertensive patients. We found higher SBPs both during daytime and nighttime in patients carrying one C allele (CT genotype; p < 0.05 and p < 0.01, respectively), which were progressively higher when patients were homozygous (CC genotype; all p < 0.01). Consistently, DBP was increased in CT carriers at nighttime (p < 0.01) and in CC carriers both daytime and nighttime (both p < 0.01).
This effect was confirmed in a multiple linear regression model (Table S1 ). While the CC genotype was associated with higher SBPs and DBPs both during daytime and nighttime (all p < 0.01, Table S1), the TT genotype was associated with lower blood pressure parameters (all p < 0.01, Table S1 ). We then analyzed the biochemical and functional parameters that could affect resistant hypertension. Table 3 shows that the studied genotypes were not associated with significant differences in the circulating levels of aldosterone, renin and cortisol. Moreover, we found no effects of the C 3435 T polymorphism on PWV (Table 3 ). 
Discussion
The main finding of our study was that resistant hypertensive patients who carried the C allele for the C 3435 T polymorphism had higher blood pressure levels when compared to carriers of CT and TT genotypes. This did not parallel with differences in plasma aldosterone levels or in PWV, a gold standard for vascular stiffness. In addition, the C allele was associated with hypertension, but not with resistant hypertension.
The MDR-1 C 3435 T polymorphism is functional, and the T allele was shown to reduce the RNA stability 23 and to affect P-glycoprotein substrate specificity. 21 Because P-glycoprotein expression seems to affect aldosterone tissue uptake and plasma disposition, 19 the presence of the T allele could lead to lower P-glycoprotein expression and increased plasma aldosterone levels, and possibly more important vascular alterations associated with hypertension. This suggestion is supported by previous findings showing increased aldosterone levels following angiotensin II infusion in subjects with the T allele. 32 However, no previous study has examined the effects of this polymorphism on the vascular function in resistant hypertensive patients.
To our knowledge, this is the first study reporting on the association of the C allele of the C 3435 T polymorphism with hypertension responsive to therapy, not associated with resistant hypertension. These findings are consistent with the higher SBP and DBP levels that we have observed in carriers of the C allele by simple association and confirmed by multiple linear regression analysis, thus correcting for gender, age, BMI and race. However, the similar aldosterone levels in subjects with different genotypes suggest that this difference is not due to any effects of the C 3435 T polymorphism on aldosterone release and disposition, even though this polymorphism affected the increases in aldosterone levels after angiotensin II infusion. 32 This discrepancy between our findings and those previously reported 32 may be explained by the fact that our patients were treated with angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors for at least six months prior to this study, whereas the study showing significant effects of this polymorphism enrolled never-treated subjects. 32 This significant difference between studies may have obscured the effects of the C 3435 T polymorphism on aldosterone release in the present study.
The association of the C allele with higher blood pressure that we found is in contrast with results published by others 27 that reported an association of higher blood pressure with the T allele. However, this effect 27 was shown only in a subset of patients who were not carriers of the CYP3A5*1 allele (not evaluated in this study), and with high urinary sodium excretion, and therefore corresponding to patients on a high-salt load diet. Without considering CYP3A5 genotypes, the authors were not able to show any effects of the C 3435 T polymorphism on blood pressure. 27 Other factors that may also explain these contrasting results are differences in patient profiles (mild hypertensive patients vs resistant hypertensive patients in the present study), ethnic differences between studied populations (including differences in CYP3A5 allelic frequencies) and drugs being used to treat patients.
The higher blood pressure levels that we found in resistant hypertensive patients carrying the C allele could be due to increased P-glycoprotein transport of other pro-hypertensive substances, such as endogenous ouabain. Supporting this suggestion, this substance was shown in association with hypertension 33 and its levels are increased in carriers of the CC genotype. 34 In addition, since resistant hypertensive patients use up to four antihypertensive drug classes, it is probable that a large number of them were using drugs Data are presented as scatter plots and means for each group. Patients were divided according to genotypes, and groups were compared by analysis of variance (ANOVA) followed by Tukey's post-test. A: systolic blood pressure was different between groups both in daytime and nighttime (both p < 0.01). TT group differed from CT and CC groups both in daytime (p < 0.05 and < 0.01, respectively) and nighttime (both p < 0.01). B: diastolic blood pressure was different between groups both in daytime and nighttime (both p < 0.01). TT group differed from CC group in daytime and nighttime (both p < 0.01) and from CT in nighttime (p < 0.01); * statistically significant. such as verapamil, diltiazem, losartan, or other drugs that have their pharmacokinetics affected by P-glycoprotein transport, 35 thus contributing to the increased blood pressure observed in subjects with the CC genotype. Finally, the association between the C allele and hypertension is also supported by recent studies showing altered renal function in hypertensive patients with particular genotypes for the C 3435 T polymorphism. 25 Subjects with the CC genotype had lower glomerular filtration rates, lower effective renal plasma flows, and higher renal vascular resistances when compared with subjects with the TT genotype, 25 and therefore it is possible that these differences between genotype groups could contribute to hypertension. The association between the CC genotype and higher blood pressure should be replicated in other populations. However, if it is confirmed, it could be useful to identify patients exposed to a higher risk who could benefit from alternative pharmacological treatments. In addition, because blood pressure values are used to define resistant hypertension, the polymorphism studied may represent an important factor in clinical practice.
This study had some important features that should be acknowledged. All resistant hypertensive subjects were extensively well characterized. All confounding factors such as heavy smoking, alcohol abuse, noncompliance to the pharmacological treatment, and secondary causes of hypertension were thoroughly investigated and eliminated from our study.
However, our study has some limitations. We studied a relatively small number of subjects because of the long-term follow up necessary for a reliable diagnosis of resistant hypertension and the exclusion of several patients in the CHTN group due to comorbidities. The low number of patients may have led us to false-negative associations, especially considering the lack of effects of the genotypes on plasma aldosterone in the RHTN group. In addition, the association we found between the CC genotype and hypertension should be taken with caution because of the low number of subjects. Moreover, we evaluated only plasma aldosterone, cortisol and renin concentrations, and we found no significant associations with genotypes. Although it was not the objective of our study, it would have been interesting to measure plasma ouabain levels. Additionally, it is possible that the effects of the genotypes studied may have been obscured by pharmacological and non-pharmacological treatment. However, it would be clearly unethical to withdraw treatment from severely hypertensive patients. Another possible limitation is that we have not ascertained the alcohol and tobacco abstinence in our patients by urine tests. Finally, the groups studied here presented some differences in frequencies of black and white subjects, and these differences may have limited our conclusions, possibly obscuring associations between genotypes and resistance to treatment.
Conclusion
Our results show an association of the CC genotype for the MDR-1 C 3435 T polymorphism with increased blood pressure in resistant hypertension, which was apparently independent of plasma aldosterone and was not paralleled by increased vascular stiffness. Further studies are necessary to validate our findings, and to examine whether these polymorphisms could be used to identify resistant hypertensive patients who could especially benefit from mineralocorticoid receptor antagonism.
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